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Abstract 
Over the years, the attention of researchers in the field of modern drug discovery and 
development has become further intense on the identification of active compounds from plant 
sources and traditional remedies, as they exhibit higher therapeutic efficacies and improved 
toxicological profiles. Among the large diversity of plant extracts that have been discovered and 
explored for their potential therapeutic benefits, a peruloside, an iridoid glycoside, has been 
proven to provide promising effects as a therapeutic agent for several diseases. Although, this 
potent substance exists in several genera, it is primarily found in plants belonging to the genus 
Eucommia. Recent decades have seen a surge in the research on Asperuloside, making it one of 
the most studied natural products in the field of medicine and pharmacology. In this review, we 
have attempted to study the various reported mechanisms of asperuloside that form the basis of 
its wide spectrum of pharmacological activities.   
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List of abbreviations: 
Abbreviations Expanded forms 
ASP Asperuloside 
ELE Eucommia green leaf extract 
HFD High fat diet 
MeOH Methanol 
RT-PCR Real time polymerase chain reaction 
mRNA Messenger RNA 
UCP1 Uncoupling protein 1 
LPS Lipopolysaccharide 
NO Nitric oxide 
TNF- Tumour necrosis factor-  
IL-6 Interleukin-6 
NF-B Nuclear factor kappa-B  
MAPK Mitogen-activated protein kinases 
PGE2 Prostaglandin E2  
iNOS Inducible nitric oxide synthase  
COX-2 Cyclooxygenase-2  
Erk1/2 Extracellular signal-regulated protein kinases 1/2  
JNK c-Jun N-terminal kinase  
IB- kappa-B-alpha  
IKKs IB-kinases  
RelA (p65) REL-associated protein 
RelB Transcription factor RelB 
ALI Acute lung injury 
ELISA Enzyme-linked immunosorbent assay 
IL-1 Interleukin 1-beta  
CAM Chorioallantoic membrane 
VEGF Vascular endothelium growth factors 
VEGFR-2 VEGF-receptor-2 
MTC Active methylene chloride 
SRB Sulforhodamine B 
CKZ Chuankezhi  
CIK Cytokine-induced killer cells 
IFN- Interferon-gamma  
CFs Clastogenic factors  
CHO Chinese hamster ovary 
AMR Antimicrobial resistance 
STC Slow transit constipation 
TXA 2 Thromboxane A2  
PGF2 Prostaglandin F-2-alpha  
SAR Structure activity relationship 
WHO The World Health Organisation 
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1. Introduction 
 
Plants and herbs have long been utilized for medicinal purposes as early as 60,000 years ago 
since the middle Paleolithic age. The World Health Organization (WHO) estimates that over 
80% of the population in developing nations resort t  traditional herbs for healing various forms 
of sicknesses (1). Over the years, many researchers have proven that herb derived remedies 
contribute to favorable health outcomes, attributed to their wide range of pharmacological effects 
and better toxicological profiles (2-13). Subsequently, plant-derived medicines have become 
novel candidates in the field of modern drug discovery and development. 
 
Various classes of natural compounds with biological a tivities have been explored; one of them 
being iridoids, which are metabolites commonly found i  plants and animals. Iridoids are known 
to represent a large and expanding group of cyclopenta-(c)-pyranmonoterpenoids, whereby, they 
can be found in large amounts in dicotyledonous plant f milies and sympetalous plant families, 
such as the Apocynaceae, Verbenaceae, Loganiaceae, and Rubiaceae (14,15). Iridoids are 
characterized by a six-membered ring with an oxygen bound to a cyclopentane ring in their 
chemical structure (Figure 1). In plants, iridoids are mostly bound to glucose, and therefore, they 
are mostly referred to as iridoid glycosides (15). Asperuloside (ASP) (Figure 2) is an example of 
a natural compound classified under the category of iridoid glycosides. It was isolated in the year 
1848 from several plants belonging to the Rubiaceae family (16). ASP has a molecular formula 
of C18H22O11 and it is a member of O-glycosyl compounds in terms of its chemical structure, in 
which a sugar group is bonded through one carbon to another group via an O-glycosidic bond. 
ASP is highly soluble in water and is a weakly acidic compound (17). In the recent years, ASP 
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has gained much interest among researchers. Numerous studies have reported on various 
medicinal properties of ASP, namely, in the treatment of obesity, inflammatory diseases, cancer, 
and bacterial infections. ASP has also been reported to be used as a laxative (7-15).  
2. Anti-obesity 
Obesity, widely recognized as the largest and fastest growing health issue globally, is 
characterized by excessive fat accumulation leading to a body mass index of more than 30 kg/m2, 
attributed to the imbalance between energy intake and expenditure (18). According to the World 
Health Organization, worldwide obesity has nearly tripled since 1975. In the year 2016, it was 
estimated that there were approximately 1.9 billion adults in the worldwide population who were 
overweight, of which over 650 million were obese (19). Obesity is usually accompanied by 
comorbidities such as type 2 diabetes, hypertension, myocardial infarction, stroke and other 
health risks. Today, obesity remains as one of the world’s leading cause of mortality, as well as a 
huge disease burden due to the lack of effective remedies (5,20). Hence, researchers are in the 
search of new, effective, plant-derived anti-obesity remedies in a bid to improve the wellbeing of 
obese patients. One of the natural compounds that have shown promising potential in the control 
of obesity is ASP, whereby, several studies have successfully demonstrated that ASP has the 
ability to supress clinical markers of obesity. 
 
A study conducted by Hirata et al., in 2011 demonstrated the potential anti-obesity effects of 
ASP. In the study, Eucommia green leaf extract (ELE) was divided into five fractions using high 
porous polystyrene gel. The fractions containing isolated geniposidic acid, ASP and chlorogenic 
acid respectively, were examined for their anti-obesity effect. Prior to the study, a 40% high-fat 
diet (HFD) was fed to mice in order to develop a metabolic syndrome-like clinical model. The 
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test substances were then chronically administered to the mice, followed by evaluation of anti-
obesity effects by observing parameters such as body weight, white adipose tissue weight, 
plasma triglyceride levels, total cholesterol levels, and free fatty acid levels after four weeks. It 
was found that the 30% MeOH fraction of ELE, which contained the higher amount of ASP than 
other fractions, had significant inhibitory effects on the observation parameters. These effects 
were also comparable with the positive control. In short, these results have proved that chronic 
administration of ASP from Eucommia leaves greatly suppressed the elevated obesity parameters 
in the experimental mice, thereby, suggesting that ASP has remarkable anti-obesity properties 
(21). 
 
In addition, Fujikawa et al., had also carried out a similar study in 2012 to examine the potential 
anti-obesity and anti-metabolic syndrome effects of ASP, as well as their mechanisms. A 
metabolic syndrome rat model was developed initially by feeding the mice with a 35 % HFD. 
The rat model was then chronically administered with ASP. The effects were studied in six rats 
over a period of three months in five different groups, namely HFD-Control, HFD-5% ELE, 
HFD-0.03% ASP, HFD-0.1% ASP, and HFD-0.3% ASP. The observed effects were then 
compared with the positive control, ELE. The results showed that ASP inhibited the increase in 
body weight, visceral fat weight, circulating levels of glucose, insulin and lipids, as well as food 
intake. Besides, ASP also stimulated the increase of plasma adiponectin levels in the HFD rats. 
All observed effects were comparable to those of standard ELE, with an exception of the 
influence on plasma glucose level. Real time polymeras  chain reaction (RT-PCR) studies 
conducted, have also demonstrated that ASP, like ELE, stimulates anti-obesity and anti-
metabolic syndrome activities in HFD rats across multiple organs, where it regulates the mRNA 
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expression of several enzymes in the metabolic pathways such as (i) diminished isocitrate 
dehydrogenase 3 and fatty acid synthase levels in the white adipose ti sue; (ii) elevated acyl-
CoA dehydrogenase and carnitine palmitoyltransferase levels in the liver; and (iii) elevated 
citrate synthase, succinyl CoA synthase and succinate dehydrogenase levels in the skeletal 
muscle. However, unlike ELE, chronic ASP administration led to a remarkable increase in the 
expression of uncoupling protein 1 (UCP1) in the brown adipose tissue of HFD rats. UCP1 is a 
gene associated with obesity and is involved in thermogenesis, regulation of energy expenditure, 
as well as in the protection against oxidative stres  (Figure 3) (22).  Hence, these results suggest 
that ASP may be a promising candidate as an anti-obesity remedy (23,24). 
3. Anti-inflammatory 
 
Inflammation occurs as a natural defence response of the body against infections, triggering the 
recruitment of macrophages to the inflammatory sites and they function to stimulate intracellular 
cascades of cytokines and chemokines through the modulation of various signalling pathways. 
The most common inflammatory trigger, lipopolysaccharide (LPS), could result in elevated 
levels of inflammatory mediators and cytokines, such as nitric oxide (NO), tumour necrosis 
factor- (TNF-) and interleukin-6 (IL-6). In the inflammatory process triggered by LPS, 
nuclear factor kappa-B (NF-B) and mitogen-activated protein kinases (MAPK) areth  two 
main signalling pathways, subsequently inducing thegene expression of pro-inflammatory 
cytokines, once these pathways are activated (5,25,26). Therefore, drug discovery researchers are 
in favour of bioactive compounds with substantial activity against NF-B and MAPK pathways, 
as they are said to be the ideal therapeutic agents in the treatment of a variety of inflammatory 
diseases (25). 
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One of the several studies that had demonstrated th anti-inflammatory effect of ASP was 
conducted by He et al., in 2018. A traditional Asian herb from the Rubiaceae family, Hedyotis 
diffusa (H. diffusa) Willd, was utilized in this particular study. This herb is being widely used as 
a traditional Chinese remedy for the treatment of inflammatory diseases such as arthritis, 
nephritis, and bronchitis. The researchers investigated the underlying mechanisms of the anti-
inflammatory activity shown by H. diffusa using the isolated iridoids from the plant on LPS-
induced RAW 264.7 cells. In the cells specifically treated by ASP, the level of inflammatory 
mediators, NO and prostaglandin E2 (PGE2), as well as the inflammatory cytokine IL-6 were 
remarkably reduced. As inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) 
are the key enzymes catalysing the productions of NO and PGE2 respectively, they are believed 
to be the mediators playing pivotal roles for a variety of inflammatory responses. Therefore, the 
protein and mRNA expression of iNOS and COX-2 were then further measured to investigate the 
underlying mechanism of the observed findings (27). The results had demonstrated that ASP 
significantly inhibited the mRNA transcript levels of iNOS and COX-2 (28,29). Typically, the 
inflammatory effects of NO are exerted through the stimulation of iNOS and COX-2. As a result 
of iNOS stimulation, prostaglandins are released anNOs are further activated, which then 
initiates the transcription of downstream inflammatory genes, namely the pro-inflammatory 
cytokines IL-1, IL-6 and TNF- (Figure 4) (27). Besides, it was also found that ASP treatment 
downregulated the phosphorylation of p38, extracellular signal-regulated protein kinases 1/2 
(Erk1/2), and c-Jun N-terminal kinase (JNK), which are the major signalling cassettes in the 
MAPK pathway (30). Being one of the most important signalling pathways in inflammatory 
responses, the MAPK pathway is essential for the expression of several inflammatory mediator 
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genes, such as COX-2, iNOS, IL-1 and TNF-. Therefore, the downregulation of p38, JNK and 
Erk1/2 is said to attenuate the activity of COX-2, which subsequently supresses inflammatory 
responses (27–30).  
 
At the same time, the cells pre-treated with ASP demonstrated significant reduction of LPS-
induced inhibition of kappa-B-alpha (IB-) phosphorylation and degradation via the NF-B 
pathway which is further elaborated in the same study by He et al. It is well known that NF-B 
signifies a large family of inducible transcription factors that regulate multiple genes that are 
involved in various processes of inflammatory responses. Besides, NF-B also plays a vital role 
in regulating the activation, differentiation, as well as effector function of inflammatory T cells 
in the human body. Subsequently, dysregulated NF-B often leads to the pathogenic processes of 
multiple inflammatory diseases (31). Generally, theregulation and activation of the NF-B is 
modulated via two main signalling pathways, namely the canonical pathway and the alternative 
pathway. In the canonical pathway, inflammatory stimul  promotes the phosphorylation of IB- 
at its two serine sites, via activation of IB-kinases (IKKs) (32). As a result of proteasomal 
degradation of IB- by IKKs, NF-B protein dimers such as RelA (p65), RelB, NF-B1 
(p105/p50) and NF-B2 (p100/52) are released, which will then induce th expression of pro-
inflammatory cytokines. In other words, the masking of the nuclear localization signals of NF-
B by IB- will result in an inactive state of NF-B protein dimers in the cytoplasm (Figure 5) 
(32–35). Therefore, any compound that suppresses IB- degradation may exhibit promising 
effect in inhibiting inflammatory cascades. Hence, these results have demonstrated that ASP 
exhibits potential anti-inflammatory property via its modulatory effects on both NF-B and 
MAPK pathways in a concentration-dependent manner (25).  
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Another similar study had been conducted by Qiu et al., in 2015, which aimed to investigate the 
anti-inflammatory effects ASP isolated from a traditional Chinese herbal medicine, Herba 
Paederiae, as well as its underlying mechanisms. The study evaluated the inflammatory 
responses in LPS-stimulated RAW 264.7 cells and LPS-induced acute lung injury (ALI) in an 
experimental rat model, whereby, the levels of pro-inflammatory cytokines were measured using 
enzyme-linked immunosorbent assay (ELISA) and Western blotting. For both in vitro and in vivo 
studies, the researchers found that ASP reduces the expr ssions of TNF-, IL-6, and interleukin 
1-beta (IL-1). In addition, it was discovered that ASP treatment in LPS-induced ALI rat model 
resulted in reduction of lung wet-to-dry weight, histological alterations, and myeloperoxidase 
activity, signifying that ASP is effective as an anti-i flammatory agent. Whereas, for the Western 
blot analysis, it was revealed that ASP has a significa t effect in the regulation of IB-, Erk1/2, 
JNK and p38 kinases in LPS-stimulated cells. All these findings demonstrates that ASP has 
substantial anti-inflammatory effect, in which its dose was directly correlated to the suppression 
of pro-inflammatory pathways, namely the NF-B and MAPK pathways (36–38). 
 
4. Anti-cancer 
Cancer is a disease that is caused by the outgrowth f clonal population of cells from body 
tissues. Carcinogenesis, a complex process referring to the development of cancer, can also be 
said to be a stepwise development functionally grouped into three different stages: (i) initiation, 
whereby the cancerous cells undergo genomic changes; (ii) promotion, whereby the development 
of tumour is accelerated by the survival and clonal expansion of the initiated cancer cells; and 
(iii) progression, whereby the cancer cells exhibit substantial increase in their size and 
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occurrence of metastasis (39). Currently, the anti-cancer therapeutics available in the market are 
highly toxic to the tumour cells. However, they also bring harmful effects to the other normal 
cells of the body at the same time. Therefore, research interest has been diverted to the discovery 
of novel anticancer therapeutics using naturally derived compounds as they are said to have 
fewer adverse effects on the human body (40,41). Several research findings have reported ASP 
to be a potential candidate as an effective alternaive to current anti-cancer therapies. Generally, 
anti-cancer effects can be modulated through several targets that act to promote apoptosis, inhibit 
angiogenesis, as well as supress proliferation and metastasis (5,42).  
Cancer is regarded as a life-threatening disease due to its ability to spread to other adjacent and 
distant organs in the body system. In this case, growth of vascular network is essential for the 
spread of cancerous cells. This physiological process of growth and development of new blood 
vessels is known as angiogenesis. As this process has a vital role in ensuring the formation and 
expansion of blood capillaries, as well as supplying nutrition and oxygen to the cancerous body 
cells, compounds that exhibit inhibitory effects ona giogenesis may be considered as a 
promising approach in the development of novel anti-cancer therapies (43–45). A recent study by 
Camero et al., in 2018 investigated the potential anti-angiogenic effects of Galium genus, a plant 
belonging to the Rubiaceae family. The plant is known to produce multiple classe  of secondary 
metabolites, which include iridoids, triterpenes, anthraquinones, and saponins. ASP was reported 
to be one of the isolated iridoids that has the highest anti-angiogenic effect among the rest of the 
metabolites, where it exhibited a dose-dependent manner on inhibiting the formation of 
microvessels in the chick embryo chorioallantoic membrane (CAM) model. This is evidenced by 
microscopic images of the CAM treated using ASP, which demonstrated a significant 67% 
reduction of blood vessel branch points, which is opposed to the control eggs that showed 
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presence of clear vascular network converging towards the embryo. Moreover, ASP also has a 
high anti-angiogenic property of 62% in respect to retinoic acid, a known compound that has 
important roles in cancer treatment, which was used as the standard in this particular study. In a 
nutshell, these findings proved that the anti-angiogenic property of ASP is beneficial to the 
treatment of cancer via the prevention of inflammation and neoplastic cell growth (45). 
However, the exact mechanisms behind such property of ASP are yet to be fully elucidated. 
Generally, anti-angiogenic effects are modulated through multiple pathways. The key signalling 
pathway that modulates proliferation of endothelial ce ls is the vascular endothelium growth 
factors (VEGF) and their receptors, whereby, downregulation of VEGF-dependent signalling 
system results in several anti-angiogenic effects such as (i) prevention of VEGF-A binding to its 
receptors; (ii) blockade of VEGF-receptor-2 (VEGFR-2); and (iii) inhibited kinase activity of 
VEGFR-2 leading to blocked growth factor signalling. Other pathways include the signalling 
systems DII4/Notch, PDGFB/PDFGR, as well as angiopoietins-1/2 (Ang1/Ang2) and their 
receptors (46–48). 
 
Another in-vitro study conducted by Artanti et al., in 2015 using the plant Hedyotis corymbosa, 
also from the Rubiaceae family, was found to suppress human breast cancer YMB-1, human 
leukemia HL60, and human oral cancer KB cell lines. In this research, the cytotoxicity property 
was investigated using (i) ethanol extract from the whole plant; (ii) the active methylene chloride 
(MTC) fraction; and (iii) a lead compound extracted via further purification of the MTC fraction. 
In this case, ASP was the lead compound isolated. Utilizing the Sulforhodamine B (SRB) 
method, the half-maximal inhibitory concentrations (IC50) of (i), (ii), and (iii) were determined 
against YMB-1, HL60 and KB cell lines. The results showed that ASP isolated from H. 
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corymbosa plant has cytotoxic activity against YMB-1, HL60 and KB cell lines with IC50 values 
of 0.7, 11.0, and 104.2 µg/mL respectively. Therefore, it was proven that ASP can be a potential 
anti-cancer compound that has comparable cytotoxic activity with antimycin A3, which is a 
control used in this study with known cytotoxicity to human breast cancer and human leukemia 
cell lines (49). Nevertheless, further studies should be conducted to unveil the mechanisms 
underlying the cytotoxic activity of ASP on these human cell lines in order to provide a new 
direction for its future use in clinical practice. 
 
On the other hand, poor cellular immunity has a great impact on cancer prognosis as it 
contributes to the proliferation and metastasis of cancer tissues. Therefore, immunotherapy had 
become a new approach in the treatment of cancers (50). Chuankezhi (CKZ) is a new Chinese 
medicine that is prepared from the extracts of M rinda officinalis and Epimedium. It is known 
that M. officinalis (Rubiaceae) comprises the dry roots of plants. CKZ contains several active 
compounds, one of which is the iridoids, which consists of ASP as one of the components in 
CKZ. A study was conducted by Zhao et al., in 2013, which aimed to determine the 
immunoregulatory effect of CKZ on cytokine-induced killer (CIK) cells. Many existing studies 
had found that activated CIK cells can exert anti-tumour activity by lysing tumours and 
preventing tumour growth in the treatment of breast cancer, renal cancer, lung cancer and 
hepatocellular carcinoma (50–54). In this study, CIK cells were generated by culturing peripheral 
blood monocytes isolated from healthy donors with interferon-gamma (IFN-) and interleukin-2. 
Utilizing cytotoxicity assay, the anti-tumour effects of CIK cells were measured on the 14th day 
after different concentrations of CKZ were added. Besides, hepatocellular carcinoma mice model 
was also used in this study. The researchers demonstrated that CKZ treatment elevated the 
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percentage of CD3+ and CD56+ CIK cells subtypes, which subsequently promoted the secretion 
of IFN- and TNF-, enhancing the function of immune-effector cells via induction of 
inflammatory cytokines production. In agreement, the results from the in vivo study revealed the 
suppression of tumour growth, most likely attributed o an increase in the number of circulating 
immune-killer cells. The apoptosis of CIK cells was l o suppressed by CKZ. Overall, CKZ, 
which contains ASP, has promising anti-tumour activity ia enhancement of CIK cells, which 
suggests that immunotherapy may contribute to improved treatment outcomes in cancer patients 
(50). However, these results may not be fully indicative that the anti-tumour effects induced by 
CKZ is attributed to the presence of ASP, as the observed anti-tumour effects may be contributed 
by other bioactive compounds in CKZ. Hence, further studies are warranted to establish a clear 
link between ASP and its possible anti-tumour propety.  
 
Furthermore, chemoprevention is regarded as another approach in the reduction in human cancer 
incidences via inhibition of carcinogenesis. Clastogens are mutagenic agents present in the 
plasma that cause disruption and breaking of the chromosomes. The damaging effects of 
clastogenic factors (CFs) are mediated by superoxide, whereby CFs are produced via superoxide 
and they further stimulate the production of superoxide by monocytes and neutrophils. 
Eventually, this leads to a clastogenic process that is self-sustained and long-lasting, which may 
surpass the capability of the body’s DNA repair system, leading to cancer (55,56). Among the 
various plant derived compounds that have been explored, ASP was found to possess 
anticlastogenic activity. According to a study by Nakamura et al., ‘Tochu’ tea, a popular 
beverage in Japan, extracted from Eucommia ulmoides leaves, was investigated for its supressing 
effect on chromosome aberrations in Chinese hamster ovary (CHO) K1 cells and male CD-1 
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mice. A total of 17 components, including ASP, were purified from the aqueous extract of 
‘Tochu’ tea leaves which were soluble in dimethyl sulfoxide. The clastogenicity of ‘Tochu’ tea 
and its components were then evaluated for up to 50% toxicity and anti-clastogenicity was 
evaluated at the concentrations at which they did not cause mitotic index depression by 
themselves. The results revealed that ASP extracted from ‘Tochu’ tea had bio-anticlastogenic 
activity, whereby, the process of mutation fixation s suppressed after the genes were damaged. 
This was attributed to the presence of an -unsaturated carbonyl group in its structure which 
reacts with enzyme thiol groups via Michael adduct formation, leading to high-order structural 
changes in the DNA (57,58). The exact anticlastogenic mechanisms of ASP in respect to its 
structure-activity relationship (SAR) are yet to be elucidated; nevertheless, it was proposed that it 
is related to the promotion of DNA re-joining process in which DNA polymerase-beta acts (57).   
5. Anti-bacterial  
The widespread incidences of antimicrobial resistance (AMR) are posing a serious global health 
concern, whereby, antimicrobials are no longer effectiv  in curing bacterial infections. Besides, 
medical researchers are unable to keep up with the pac  of antimicrobial drug discovery to 
combat the emerging resistant pathogens. Therefore, res archers are now searching for novel 
antimicrobial compounds that exhibit broad spectrum action against both Gram-positive and 
Gram-negative bacteria with minimal adverse effects to the human body (59,60). For this 
purpose, a variety of plant-derived compounds have be n explored for their anti-bacterial 
property, among which ASP had demonstrated antimicrob al effects against multiple bacteria 
strains, making it a potential candidate in combating AMR. 
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Morinda citrifolia, known as the Noni plant, is a popular traditional medicine that have been 
widely used as a dietary supplement and to cure a bro d range of illnesses, as it contains 
phytochemicals that have multiple therapeutic effects (61,62). A variety of compounds have been 
identified in the Noni plant, whereby in a study by Leach et al., L-asperuloside was proven to 
show anti-bacterial effect against several infectious strains, such as Pseudomonas aeruginosa, 
Staphlylococcus aureus, Proteus morganii, Bacillus subtilis, Escherichia coli, Shigella and 
Salmonella (63). In agreement, Bushnell et al., have also reported that L-asperuloside exhibited 
moderate antibacterial properties against infectious bacteria strains such as Pseudomonas 
aeruginosa, Micrococcus pyogenes, Escherichia coli, Pseudomonas aeruginosa, Proteus 
morganii, Staphylococcus aureus, Bacillus subtilis, Salmonella, and Shigella (3). On the other 
hand, a study by Bhardwaj et al., evaluated the antimicrobial activity of M. citrifolia gel for the 
elimination of bacteria in root canal treatment. It was discovered that L-asperuloside contributed 
to 86.02% microbial inhibition at depths of 200 and 400 µm (64). In a nutshell, ASP can 
potentially be utilized for the treatment of infection-related illnesses, in which its antimicrobial 
effect is theoreticized by various mechanisms, such as (i) its antioxidative property which 
counteracts free-radicals and metabolites; (ii) enhanced activity of cortisol that promotes blood 
circulation, removing bacterial toxins from the body; (iii) promotion of humoral and cell-
mediated immune function, enhancing antigenic surveillance; and (iv) blocking NF-B pathway 
and mitogenic responses in infected cells (65). 
6. Laxatives 
Constipation, a condition characterized by uncomfortable and infrequent bowel movement, is 
often associated with decreased mental health and social functioning. As the condition is rarely 
attributed to a life-threatening disease, empirical therapy is the first-line management option 
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recommended by current guidelines. As a result, more than half of the treated patients are 
unsatisfied with their treatment, most likely due to limited efficacy of drugs that do not target the 
underlying pathophysiology, alongside the association with adverse effects (66). Therefore, 
alternative compounds are needed to be explored for the development of novel therapeutic agents 
for constipation, including plant-derived compounds. 
 
Galium aparine, or cleaver is an example of traditional herb that ws studied for its laxative 
property. ASP is present as one of the valuable constituents in cleaver, and researchers have 
found that ASP has mild laxative action. This can be attributed to the ability of ASP to convert 
into prostanoid intermediates in the body (67,68). A study by Cong et al., in 2007 was conducted 
to evaluate the mechanism underlying slow transit constipation (STC), which is a type of 
constipation characterized by reduced motility within the large intestine. The results suggested 
that lowered basal motility in STC patients was generally caused by low levels of thromboxane 
A2 (TXA2) and prostaglandin F-2-alpha (PGF2), leading to reduced muscle contraction and 
elevated levels of prostaglandin E2 (PGE2) which induced relaxation (69). Therefore, it was 
believed that ASP can play an essential role in the promotion of bowel movement through 
modulating the level of prostaglandin analogues in the body and subsequently, treating 
constipation. Besides that, there were studies that suggested SAR may also play a role in the 
purgative action of ASP, whereby presence of a freehydroxyl group at C-11 remarkably 
inhibited purgative activity; and the presence of hydroxyl-/-oxy group at C-6 presented delayed 
onset of action (70). Nonetheless, the studies conducte  on the purgative effects of ASP are 
limited and may not be sufficient to support its use as a medicinal laxative. Further studies may 
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be warranted to clarify the potential of ASP as a laxative and to uncover its underlying 
mechanism. 
 
Conclusion 
The popularity of plant extracts and molecules as medicinal natural products is increasing, and it 
is widely used for the overall maintenance of good health. Based on the evidences and results 
from the previous studies conducted on asperuloside from multiple plant sources, it is with no 
doubt justified that asperuloside has many therapeutic benefits that are believed to be modulated 
through various signalling pathways. Nevertheless, the results in both in vivo and in vitro studies 
are not significant enough to be used on human subjects due to lack of pre-clinical and clinical 
trials. Therefore, in paving a new direction in thefield of drug discovery and development, more 
extensive studies are required to be performed in terms of the pharmacokinetic properties, as 
well as the identification of quality, safety, risk of toxicity and exact mechanism of action 
underlying the observed pharmacological properties of asperuloside. Furthermore, well-planned 
and systematically executed clinical studies are essential to evaluate the practicability of 
asperuloside for therapeutic use in humans.  
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Figure Ligands:  
Figure 1: Chemical structure of iridoids. 
Figure 2(a): The chemical structure of asperuloside (C18H22O11). 
Figure 2(b): The three-dimensional chemical structure of asperuloside (C18H22O11). The atoms are represented as: hydrogen (white), 
carbon (grey), oxygen (red). 
Figure 3: An illustration of the location and function of UCP1 in the mitochondrial respiratory chain (MRC) in brown adipose tissue. 
UCP1 is located on the mitochondrial inner membrane d functions to uncouple oxidative mechanism from the synthesis of ATP, 
leading to dissipation of energy via heat release (22). 
Figure 4: An illustration of role of nitric oxide (NO), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) and 
their effects on inflammatory responses. 
Figure 5: An illustration of the role of inhibitor of kappa-B-alpha (IB-) in NF-B signalling and its effect on inflammation. The 
binding of inflammatory cytokines to receptors generat s signals that activates IB kinases (IKKs), which subsequently induces 
phosphorylation and proteosomal degradation of IB-. The resulting free NF-B protein dimers such as RelA and NF-B1 will then 
translocate into the nucleus and activate transcription of the target genes that are responsible for the encoding of pro-inflammatory 
cytokines (34,35). 
Figure 6: Summary of the proposed fundamental mechanisms of asperuloside. Further studies are warranted to elucidate the exact 
mechanisms responsible for its various therapeutic properties. 
Table 1: A summary of the effect of asperuloside and its proposed mechanism of action on various types of cancers. 
Type of 
cancer 
Effect of asperuloside Proposed mechanism of action Reference 
Breast cancer - Inhibits the formation of new cancer 
cells. 
- Restores breast tumour-induced 
osteolysis. 
- Asperuloside inhibits metastasis and angiogenesis 
through modulation of signaling pathways such as 
VEGF, DII4.Notch and Ang1/Ang2, thereby 
destroying new cancer cells. 
- Immunomodulation of T cells, MDSC population 
and anti-tumour cytokine IL-12. 
(49,71) 
Leukemia Inhibits further growth and destroys cancer 
cells. 
- Asperuloside displays cytotoxic activity through 
modulation of the VEGF signaling system. 
 
(49) 
Liver cancer 
 
Suppresses the growth of tumour. 
 
- Asperuloside promotes secretion of IFN-	 and TNF-
	, thereby enhancing the function of immune-
effector cells. 
- Asperuloside enhances the effect of cytokine-
induced killer (CIK) cells. 
 
(50) 
Colorectal 
cancer 
Inhibits the growth and formation of 
cancer cells. 
- Asperuloside increases depolarization of the 
mitochondrial membrane, inducing apoptosis. 
- Asperuloside elevates caspase activities and ROS 
generation, promoting apoptotic cell death. 
 
(72) 
 
 
Table 2: A summary of the major therapeutic properties of asperuloside documented in various studies. 
Property Findings Type of study Source(s) of 
asperuloside 
Reference 
Anti-obesity Significant inhibitory effects of ASP on body weight, 
white adipose tissue weight, plasma triglyceride levels, 
total cholesterol levels, and free fatty acid levels. 
In-vivo on 40% high-
fat diet model mice 
Eucommia leaves (21) 
- ASP inhibits increase in body, visceral fat weight, 
circulating levels of glucose, insulin and lipids, a  
well as food intake. 
- Stimulated the increase of plasma adiponectin 
levels. 
In-vivo on 35% high-
fat diet model mice 
Eucommia leaves (23) 
- Significant reduction of body weight with no 
chances in food intake. 
- MC4R protein expression significantly elevated in 
the nucleus accumbens of model mice. 
In-vivo on high-fat diet 
C57B/6 mice 
N/A (73) 
Increases the production of adenosine 5’-triphosphate 
in white adipose tissue and increases utilization of 
ketone bodies and glucose in the skeletal muscle. 
In-vivo on obese 
female Wistar rats 
induced by 
ovariectomy; and high-
fat diet mice 
Eucommia leaves (74) 
Observed significant reduction in body weight, body 
mass index, as well as fat tissues. 
In-vivo on obese 
female Wistar rats 
Eucommia leaves (75) 
induced by 
ovariectomy 
Anti-
inflammatory 
Remarkable reduction of inflammatory mediators such 
as nitric oxide and prostaglandin E2, and inflammatory 
cytokines such as interleukin-6. 
In-vitro on LPS-
induced RAW 264.7 
cells 
H. diffusa (25) 
- Suppressed expression of IL-1, TNF- and IL-6. 
- Reduction of lung wet-to-dry weight, histological 
alterations, and myeloperoxidase activity. 
In-vitro on LPS-
induced RAW 264.7 
cells and in-vivo on 
LPS-induced acute 
lung injury mice model 
Herba Paederiae (36) 
Inhibited the release of TNF- with IC50 value of 0.52 
µg/mL in the treatment of rheumatoid arthritis.  
In-vitro on cultured 
mouse peritoneal 
macrophages 
Lasianthus 
acuminatissimus 
(76) 
Suppressed plasma levels of inflammatory cytokine 
TNF-, producing anti-inflammatory and anti-colitis 
effects. 
In-vivo on chronic 
dextran sulfate sodium-
induced colitis mice 
model 
Eucommia 
ulmoides 
(77) 
Anti-cancer Demonstrated dose-dependent manner on the 
inhibition of microvessels formation. 
In-vivo on chick 
embryo chorioallantoic 
membrane model 
Galium genus (45) 
Demonstrated cytotoxicity against human YMB-1 
(breast cancer), HL60 (leukemia) and KB (oral cancer) 
In-vitro on human 
cancer cell lines 
Hedyotis 
corymbosa 
(49) 
cell lines. 
- Elevated percentage of cytokine-induced killer 
cells subtypes CD3+ and CD56+.  
- Promoted the secretion of IFN-γ and TNF-α. 
- Enhanced function of immune-effector cells. 
- Suppression of tumour growth. 
- Suppressed apoptosis of cytokine-induced killer 
cells. 
In-vitro on cytokine-
induced killer cells and 
in-vivo on 
hepatocellular 
carcinoma mice model 
Morinda officinalis 
and Epimedium M. 
officinalis 
(50) 
Demonstrated bio-anticlastogenic activity, whereby the 
process of mutation fixation is suppressed after th 
genes are damaged. 
In-vitro on Chinese 
hamster ovary (CHO) 
K1 cells and in-vivo on 
male CD-1 mice 
Eucommia 
ulmoides leaves 
(57) 
- Inhibited proliferation of HT-29 cells for 24 hours. 
- Increased mitochondrial membrane depolarization.  
- Increased ROS generation and caspase activities. 
- Increased number of cells in sub-G1 peak in dose-
dependent manner. 
In-vitro on HT-29 
human adenocarcinoma 
cells 
Oldenlandia 
diffusa 
(72) 
Anti-bacterial Effective against Pseudomonas aeruginosa, 
Staphlylococcus aureus, Proteus morgaii, Baciillis 
subtilis, Escherichia coli, Shigella and Salmonella. 
In-vitro against Gram-
positive and Gram-
negative bacteria 
Morinda citrifolia (63) 
Effective against Pseudomonas aeruginosa, 
Micrococcus pyrogenes, Escherichia coli, 
In-vitro against Gram-
positive and Gram-
Morinda citrifolia (3) 
Pseudomonas aeruginosa, Proteus morgaii, 
Staphylococcus aureus, Bacillis subtilis, Salmonella, 
and Shigella. 
negative bacteria 
Exhibited 86.02% microbial inhibition in the root 
canal at both 200 and 400 µm. 
In-vitro using dentin 
shavings collected at 
200 and 400 µm 
Morinda citrifolia (64) 
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Figure 2(a): The chemical structure of asperuloside (C18H22O11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2(b): The three-dimensional chemical structure of asperuloside (C18H22O11). The atoms 
are represented as: hydrogen (white), carbon (grey), oxygen (red). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: An illustration of the location and function of UCP1 in the mitochondrial respiratory 
chain (MRC) in brown adipose tissue. UCP1 is located on the mitochondrial inner membrane 
and functions to uncouple oxidative mechanism from the synthesis of ATP, leading to dissipation 
of energy via heat release (22). 
 
 
 
 
 
 
 
 
 
Figure 4: An illustration of role of nitric oxide (NO), inducible nitric oxide synthase (iNOS), 
and cyclooxygenase-2 (COX-2) and their effects on inflammatory responses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: An illustration of the role of inhibitor of kappa-B-alpha (IB-) in NF-B signalling 
and its effect on inflammation. The binding of inflammatory cytokines to receptors generates 
signals that activates IB kinases (IKKs), which subsequently induces phosphorylation and 
proteosomal degradation of IB-. The resulting free NF-B protein dimers such as RelA and 
NF-B1 will then translocate into the nucleus and activate transcription of the target genes that 
are responsible for the encoding of pro-inflammatory cytokines (31,32). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Summary of the proposed fundamental mechanisms of asperuloside. Further studies 
are warranted to elucidate the exact mechanisms responsible for its various therapeutic 
properties. 
 
Highlights 
• Asperuloside have potent medicinal properties including antiobesity and anti-
inflammatory 
• Asperuloside inhibited the increase in body weight and visceral fat weight 
• The anti-inflammatory mechanism of Asperuloside was demonstrated in LPS-induced 
RAW 264.7 cells. 
• The anticancer activity of Asperuloside was comparable with antimycin A3 
• Asperuloside also demonstrated moderate antibacterial effects on several known 
microbes 
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